866-997-4948(US-Canada Toll Free)

Stimuvax (Non Small Cell Lung Cancer) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Non Small Cell Lung Cancer

No. of Pages : 35 Pages

 

GlobalDatas pharmaceuticals report, Stimuvax (Non Small Cell Lung Cancer)- Analysis and Forecasts to 2020 provides Stimuvax sales forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes information on Non Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData\'s team of industry experts.

 

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Stimuvax including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Stimuvax including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts for 2012-2020 for Stimuvax in the US, EU-5, Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 NSCLC Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 Tobacco 6
2.3.2 Radon 6
2.3.3 Asbestos 7
2.3.4 Other Environmental Agents 7
2.4 GlobalData Report Guidance 9


3 NSCLC Disease: Market Characterization 10
3.1 NSCLC Disease Market 10
3.2 NSCLC Disease Market Forecasts and CAGR 10
3.3 Drivers for the NSCLC Disease Market 11
3.3.1 High Incidence 11
3.3.2 High Mortality Rate 12
3.3.3 Increased Use of Chemotherapy in Early Stages of NSCLC 12
3.3.4 Emergence of Targeted Drugs and Maintenance Therapy 12
3.3.5 Promising Pipeline Drugs 12


4 Tumor-Node-Metastases (TNM) Classification of NSCLC 13


5 Stimuvax (BLP25 liposome vaccine) 16
5.1 Introduction 16
5.2 Mechanism of Action 16
5.3 Clinical Studies of Stimuvax 16
5.3.1 Phase II trial 16
5.3.2 Phase III trial 17
5.4 Fast Track Designation 17
5.5 Milestone payment from Merck KGaA 17
5.6 Factors Affecting Sales 18
5.6.1 NSCLC Market 18
5.6.2 Higher survival 18
5.6.3 Helps Reducing Disease Progression 18
5.6.4 Hold by FDA on the Vaccine 18
5.7 Drug Evaluation 19
5.7.1 Drug Risk Benefit Score 19
5.7.2 Intensity of Competition 21
5.8 Sales forecast 21
5.8.1 Target patient Pool of Stimuvax 21
5.8.2 Dosing 22
5.8.3 Market Penetration 23
5.8.4 Annual Cost of Therapy 23
5.8.5 Sales Projections of Stimuvax 23


6 NSCLC Market: Appendix 30
6.1 Market Definitions 30
6.2 Abbreviations 30
6.3 Research Methodology 30
6.3.1 Coverage 31
6.3.2 Secondary Research 31
6.3.3 Forecasting 31
6.3.4 Number of Patients Approved to take the Drug 32
6.3.5 Net Penetration of Drug 32
6.3.6 Net Annual Dosing 34
6.3.7 Annual Cost of Therapy 34
6.3.8 Primary Research 34
6.3.9 Expert Panels 34
6.4 Contact Us 34
6.5 Disclaimer 35
6.6 Sources 35

List of Table


Table 1: NSCLC, Incidences and Mortality, 20082030 5
Table 2: NSCLC, Global, Market Size Forecast ($bn), 20092020 10
Table 3: Drug Risk Benefit Score of Stimuvax 19
Table 4:Stimuvax,NSCLC, Global Sales Forecast ($m), 2012-2020 24
Table 5:Stimuvax,NSCLC, the US, Sales Forecast($m), 2012-2020 25
Table 6: Stimuvax,NSCLC, UK,Sales Forecast ($m), 2012-2020 25
Table 7:Stimuvax, NSCLC, France, Sales Forecast($m), 2012-2020 26
Table 8: Stimuvax, NSCLC, Germany, Sales Forecast($m), 2012-2020 27
Table 9: Stimuvax,NSCLC, Italy, Sales Forecast($m), 2012-2020 27
Table 10:Stimuvax, NSCLC, Spain, Sales Forecast($m), 2012-2020 28
Table 11: Stimuvax,NSCLC, Japan, Sales Forecast($m), 2015-2020 29

List of Chart


Figure 1: Percentage Distribution of Top 20 Cancers 4
Figure 2: Difference of % Distribution of Incidence and Mortality of Top 20 Cancers 5
Figure 3: Percentage Distribution of Different Types of NSCLC according to Incidence, 2008 6
Figure 4: % Share of Risk Factors in Developed Countries 7
Figure 5: Per Capita Cigarette Consumption, The US, 1976-2006 8
Figure 6: NSCLC, Global, Market Size Forecast ($bn), 20092020 10
Figure 7: NSCLC, Global, Incidence (in millions), 2008-2030 11
Figure 8: Oncology, Global, Incidence (in millions), 2008-2030 11
Figure 9: Broad Classification of NSCLC 13
Figure 10: Detailed TNM Classification 14
Figure 11: Classification of NSCLC 15
Figure 12:Efficacy comparison on the basis of response rate of the drugs 20
Figure 13: Efficacy comparison on the basis of survival rate (months) 20
Figure 14: Drug Model Diagram of Stimuvax 22
Figure 15: Distribution of Stimuvax sales in Major Countries 23
Figure 16:Stimuvax,: NSCLC, Global Sales Forecast($m) ,2012-2020 24
Figure 17:Stimuvax, NSCLC, the US, Sales Forecast($m) ,2012-2020 24
Figure 18: Stimuvax,NSCLC, UK, Sales Forecast ($m),2012-2020 25
Figure 19: Stimuvax,NSCLC, France, Sales Forecast($m) ,2012-2020 26
Figure 20: Stimuvax, NSCLC, Germany, Sales Forecast($m), 2012-2020 26
Figure 21: Stimuvax, NSCLC, Italy, Sales Forecast ($m), 2012-2020 27
Figure 22:Stimuvax,NSCLC, Spain, Sales Forecast ($m) ,2012-2020 28
Figure 23: Stimuvax, NSCLC, Japan, Sales Forecast ($m) ,2015-2020 28
Figure 24: GlobalData Methodology 30
Figure 25: Drug Model Diagram 33
Figure 26: Patients Approved for the Drug 33

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *